Last reviewed · How we verify
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).
Details
| Lead sponsor | Realm Therapeutics, Inc. |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 96 |
| Start date | Sun Dec 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Jan 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Allergic Conjunctivitis
Interventions
- PR013 (0.045%)
- PR013 (0.06%)
- Vehicle
Countries
United States